Evommune, Inc.
EVMN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$218.26M
Close$
$-24.35
503.1% downside
Current Fair Value
503.1% downsideOvervalued by 503.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $218.26 Million |
|---|---|
| Enterprise Value | $166.34 Million |
| Earnings per Share | $-11.22 |
| Beta | 0.96 |
| Outstanding Shares | 36,135,644 |
Return
| Return on Equity | -34.10% |
|---|---|
| Return on Assets | -31.35% |
| Return on Invested Capital | -35.52% |
Valuation & Multiples
| P/E Ratio | -2 |
|---|---|
| PEG | -1.45 |
| Price to Sales | - |
| Price to Book Ratio | 0.86 |
| Enterprise Value to Revenue | 16.63 |
| Enterprise Value to EBIT | -1.65 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 16, 2026
EPS Estimate
$-0.82
Consensus analyst estimateRevenue Estimate
$500,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 141.58% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.72%▼ 95.36% |
|---|---|
| Total Invested | $2.15M▼ 99.54% |
| Investors Holding | 11▼ 105.00% |
About Evommune, Inc.
45 employees
CEO: Luis C. Pena
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sponta...